Carmustine
Based on 11 publication(s) in Google Scholar
Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 154-93-8
- Formula: C5H9Cl2N3O2
- Molecular Weight:214.05
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Carmustine
More- Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]
- Biomaterials. 2022 May;284:121533. [Abstract]
- Adv Healthc Mater. 2026 Jun 10:e71322. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- J Drug Deliv Sci Technol. 9 September 2022, 103770.
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Cancer Sci. 2026 Mar;117(3):695-710. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Mol Imaging Biol. 2020 Feb;22(1):124-133. [Abstract]
- SSRN. 2026 Jan 26.
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
Biological Activity
DNA Alkylator[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A 172 | IC50 |
18 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| A-427 | IC50 |
8 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| A498 | IC50 |
110 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| A549 | IC50 |
90 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| Astrocyte | IC50 |
155.6 μM
Compound: BCNU
|
Cytotoxicity against rat astrocytes
Cytotoxicity against rat astrocytes
|
[PMID: 16970409] |
| Astrocyte | EC50 |
54.8 μM
Compound: 1, BCNU, Carmustine
|
Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method
|
10.1007/s00044-010-9356-8 |
| C6 | IC50 |
9.3 μM
Compound: BCNU
|
Cytotoxicity against rat C6 glioma cell line
Cytotoxicity against rat C6 glioma cell line
|
[PMID: 16970409] |
| C6 | EC50 |
4.8 μM
Compound: 1, BCNU, Carmustine
|
Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method
|
10.1007/s00044-010-9356-8 |
| CCD 19Lu | IC50 |
300 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| CHO | IC50 |
8.2 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against CHO cell line
Dose required to inhibit cell growth was determined against CHO cell line
|
[PMID: 11262080] |
| DOD-1 | IC50 |
37 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| HL-60 | IC50 |
30.5 μM
Compound: BCNU
|
Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay
|
10.1007/s00044-011-9778-y |
| HT-29 | IC50 |
17 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma
Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma
|
[PMID: 11262080] |
| K562 | IC50 |
9 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia
Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia
|
[PMID: 11262080] |
| L1210 | IC50 |
4.5 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia
|
[PMID: 11262080] |
| L1210 | ED50 |
4 μM
Compound: BCNU
|
Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.
|
[PMID: 2939245] |
| L1210 | ED50 |
4 μM
Compound: BCNU
|
Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis
|
[PMID: 563461] |
| L1210 | ED50 |
4 μM
Compound: BCNU
|
In vitro inhibitory activity against murine leukemia L1210 cells
In vitro inhibitory activity against murine leukemia L1210 cells
|
[PMID: 6256551] |
| L1210 | ED50 |
20 mg/kg
Compound: Table III, R37C1
|
Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days
|
[PMID: 836500] |
| LOX IMVI | IC50 |
7 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| Malme-3M | IC50 |
20 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| MCF7 | IC50 |
4.5 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| MDA-MB-231 | IC50 |
7.4 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma
Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma
|
[PMID: 11262080] |
| NCH89 | IC50 |
615 μM
Compound: Carmustine
|
Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs
|
[PMID: 20329733] |
| NCI/ADR-RES | IC50 |
20 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H125 | IC50 |
9 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H23 | IC50 |
5 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H322M | IC50 |
60 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H358 | IC50 |
98 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H460 | IC50 |
80 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| NCI-H520 | IC50 |
20 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay
|
[PMID: 2391696] |
| OVCAR-3 | IC50 |
15 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| OVCAR-4 | IC50 |
18 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| P388 | IC50 |
5.9 μM
Compound: Carmustine
|
Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia
Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia
|
[PMID: 11262080] |
| P388 | ED50 |
13.3 μM
Compound: BCNU
|
Mean value for the exposure for P388 to the drug for a period of 60 min
Mean value for the exposure for P388 to the drug for a period of 60 min
|
[PMID: 6226795] |
| P388 | ED50 |
6.3 μM
Compound: BCNU
|
Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree
Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree
|
[PMID: 6226795] |
| SF-126 | IC50 |
20 μM
Compound: BCNU
|
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
|
[PMID: 27041398] |
| SF-126 | IC50 |
25 μM
Compound: BCNU
|
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
|
[PMID: 27041398] |
| SF-126 | IC50 |
55 μM
Compound: BCNU
|
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
|
[PMID: 28197307] |
| SF-126 | IC50 |
85 μM
Compound: BCNU
|
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
|
[PMID: 28197307] |
| Sf21 | IC50 |
>1000 μM
Compound: Carmustine
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
>1000 μM
Compound: Carmustine
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| SK-MEL-5 | IC50 |
27 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| TE-671 | IC50 |
25 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| U-251 | IC50 |
15 μM
Compound: BCNU
|
Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
|
[PMID: 2391696] |
| U-87MG ATCC | IC50 |
1.42 μM
Compound: BCNU
|
In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr
|
[PMID: 15603970] |
| U-87MG ATCC | IC50 |
3.9 μg/mL
Compound: Carmustine
|
Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33276991] |
| U-87MG ATCC | IC50 |
3.9 μM
Compound: Carmustine
|
Antiproliferative activity against human U87 cells
Antiproliferative activity against human U87 cells
|
[PMID: 33421712] |
| U-87MG ATCC | IC50 |
3.9 μg/mL
Compound: BCNU
|
Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay
|
10.1007/s00044-012-0249-x |
| U-937 | IC50 |
12.3 μM
Compound: BCNU
|
Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay
|
10.1007/s00044-011-9778-y |
Carmustine is an antitumor chemotherapeutic agent. Carmustine (8, 80, and 800 μM) decreases N-acetyltransferase (NAT) activities for 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) in rat glial tumor cytosol and intact cells. In rat glial tumor cells, the DNA-AF adduct increases, and carmustine decreases the formation of DNA-AF adduct[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 154-93-8
-
Appearance <30°C Solid,>30°C Liquid
-
Molecular Weight 214.05
-
Formula C5H9Cl2N3O2
-
Color White to yellow
-
SMILES
O=C(NCCCl)N(CCCl)N=O
-
Synonyms
BCNU
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
2024 Sep;26(9):1545-1557. PMID: 38997456
Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]
C57BL/6J mice bearing GSDME-overexpressing murine melanoma B16 cell-derived xenografts were treated intraperitoneally with Carmustine (20 mg/kg) and RSL3 (10 mg/kg) daily for 1 week. Xenograft tumours and their corresponding tumour weights are indicated (n = 7). PBS was used as a control. The results demonstrated that the combination of Carmustine and RSL3 effectively suppressed tumor growth.
Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]
RSL3 (100 nM) combined with different reagents, including MMS (methyl methanesulfonate, 1 mM), MNNG (N-methyl-N’-nitro-N’-nitrosoguanidine, 0.3 mM) and Carmustine (0.25 mM)), were used to treated cells, the pyroptotic morphologies were observed. RSL3 combined with lower dose of UVC irradiation (50 mJ cm-2) was used as a positive control.
-
Biomaterials
A Sub-6 nm MnFe2O4-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy. [Abstract]2022 May;284:121533. PMID: 35462304
Carmustine purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 May;284:121533. [Abstract]
Quantitative analysis of intracellular GSH using flow cytometry. Carmustine was used as positive control. ROS and GSH analysis were performed with 4T1 cells upon treatment for 6 h.
-
Adv Healthc Mater
Forming a Precise and Reproducible Hypoxic Tumor Microenvironment in Glioblastoma by High Cell Density Bioprinting. [Abstract]2026 Jun 10:e71322. PMID: 42272125 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Carmustine purchased from MedChemExpress. Usage Cited in: J Drug Deliv Sci Technol. 9 September 2022, 103770.
Dose response curves of free drugs and drug-loaded nanoparticles. In vitro cell viability assays of U251 cells after 48 h of incubation with Carmustine (BCNU, 62.5-500 μM), BCNU-loaded Fe3O4@MIL-88B–NH2 nanocomposites.
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Cancer Sci
Resveratrol as a Novel YAP Inhibitor Targeting Glioblastoma Progression and Sensitizing to Chemotherapy. [Abstract]2026 Mar;117(3):695-710. PMID: 41518046
Carmustine purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2026 Mar;117(3):695-710. [Abstract]
RV increases the sensitivity of GBM cells to chemotherapeutic agents. Graphs show GBM cell viability after 48 h treatment with 50 μM RV combined with 50 μM TMZ or 50 μM Carmustine (BCNU), compared to DMSO and untreated controls (Ctrl).
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Mol Imaging Biol
Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23. [Abstract]2020 Feb;22(1):124-133. PMID: 30989436 -
Solvent & Solubility
DMSO : 100 mg/mL (467.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (467.18 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (467.18 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
The determination of Acetyl-CoAdependent N-acetylation of 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) are performed. Incubation mixtures in the assay system consists of a total volume of 90 μL: glial tumor cells cytosols, diluted as required, in 50 μL of lysis buffer (20 mM Tris/HCl, pH 7.5, 1 mM DTT and 1 mM EDTA), 20 μL of an Acetyl-CoA recycling mixture of 50 mM Tris-HCl (pH7.5), 0.2 mM EDTA, 2 mM DTT, 15 mM acetylcamitine, 2U/mL carnitine acetyltransferase, and AF or PABA at specific concentrations. The reactions are started by addition of 20 μL of Acetyl-CoA. The control reactions have 20 μL distilled water in place of Acetyl-CoA. For the single point activity measurements, the final concentration of AF or PABA is 0.1 mM and AcCoA is 0.5 mM. The reaction mixtures with or without specific concentrations of Carmustine and lomustine are incubated at 37°C for 10 min and stopped with 50 μL of 20% trichloroacetic acid for the PABA reactions, and 100 μL of acetonitrile for the AF reactions. All of the reactions (experiments and controls) are run in triplicate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[2]
Individual rats are weighted prior to enter the study; their weights are recorded, and they are randomLy assigned to four groups. Group I (saline group); This group consists of 12 rats. These rats are injected with 2 mL/kg of saline intraperitoneally (IP) 48 h before the study, being included by the study 48 h later. Group II (corn oil group) consists of 15 rats. These rats are injected with 2 mL/kg of corn oil (vehicle) IP 48 h before the study. Group III (Carmustine group) consists of 16 rats. These rats are injected with 1 mL per day of saline IP, administered at the same hour of the day as a single-dose for 3 days. Twelve hours after the first dose of saline, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine. Group IV (trimetazidine group) consists of 12 rats. These rats are injected with 2.5 mg/kg per day of trimetazidine (TMZ) IP, administered at the same hour of the day as a single-dose for 3 days. 12 h after the first dose of TMZ, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hung CF. Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. Neurochem Res. 2000 Jun;25(6):845-51. [Content Brief]
[2]. Demir A, et al. The effect of trimetazidine on intrahepatic cholestasis caused by carmustine in rats. Hepatol Res. 2001 May 1;20(1):133-143. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 4.6718 mL | 23.3590 mL | 46.7181 mL | 116.7951 mL |
| 5 mM | 0.9344 mL | 4.6718 mL | 9.3436 mL | 23.3590 mL | |
| 10 mM | 0.4672 mL | 2.3359 mL | 4.6718 mL | 11.6795 mL | |
| 15 mM | 0.3115 mL | 1.5573 mL | 3.1145 mL | 7.7863 mL | |
| 20 mM | 0.2336 mL | 1.1680 mL | 2.3359 mL | 5.8398 mL | |
| 25 mM | 0.1869 mL | 0.9344 mL | 1.8687 mL | 4.6718 mL | |
| 30 mM | 0.1557 mL | 0.7786 mL | 1.5573 mL | 3.8932 mL | |
| 40 mM | 0.1168 mL | 0.5840 mL | 1.1680 mL | 2.9199 mL | |
| 50 mM | 0.0934 mL | 0.4672 mL | 0.9344 mL | 2.3359 mL | |
| 60 mM | 0.0779 mL | 0.3893 mL | 0.7786 mL | 1.9466 mL | |
| 80 mM | 0.0584 mL | 0.2920 mL | 0.5840 mL | 1.4599 mL | |
| 100 mM | 0.0467 mL | 0.2336 mL | 0.4672 mL | 1.1680 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.